한글목차

세계 면역 분석 시장 규모는 2023년 350억 달러에 달할 것으로 예상됩니다.

이 시장은 예측 기간 동안 5.9%의 CAGR로 성장하여 2028년에는 467억 달러 규모에 이를 것으로 예상됩니다. 시장 성장의 원동력은 만성 질환 및 감염성 질환의 유병률 증가, 시스템 및 기술 혁신, 정부 지원 정책 및 이니셔티브, 약물 및 알코올 남용 증가, 약물 및 알코올 검사를 의무화하는 엄격한 법률 등의 요인입니다.

시장 성장을 주도하는 주요 요인은 다양한 진단 절차에서 시약 및 키트의 반복적인 사용과 세계적으로 시행되는 면역 분석 기반 검사 증가입니다. 또한, 효율적인 결과와 진단 정확도를 제공하는 우수한 시약 및 키트의 가용성이 이 분야의 성장을 주도하고 있습니다.

CLIA 검사는 ELISA, 방사성동위원소 분석과 같은 다른 기술에 비해 민감도, 넓은 동적 범위, 우수한 속도, 간섭 감소, 높은 특이성 등의 장점으로 다양한 만성 질환 및 감염성 질환의 효율적인 진단에 도움이 됩니다.

세계 면역 분석 시장은 감염성 질환, 순환기, 내분비, 종양, 뼈 및 미네랄 질환, 자가 면역 질환, 혈액 검사, 알레르기 진단, 약물 모니터링 및 검사, 신생아 검사, HIV/AIDS, 말라리아, 간염, 기타 응용 분야로 분류됩니다, 인플루엔자 등 질병의 발병률 증가와 함께 감염성 질환의 신속한 진단이 주된 이유입니다.

아시아태평양은 예측 기간 동안 면역 분석 시장에서 가장 높은 성장률을 보일 것으로 예상됩니다. 이 지역의 높은 성장세는 대상 인구가 많고, 아시아 국가들의 만성질환 유병률이 증가하고 있기 때문입니다.

이 보고서는 세계 면역 분석 시장을 조사했으며, 제품별, 기술별, 시료별, 용도별, 최종사용자별, 지역별 동향과 시장 진출기업 프로파일 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 규제 분석
• 기술 분석
• 무역 분석
• 특허 분석
• 밸류체인 분석
• 공급망 분석
• 생태계/시장 맵
• Porter의 Five Forces 분석
• 2023년-2024년 주요 컨퍼런스 및 이벤트
• 가격 분석
• 주요 이해관계자와 구입 기준
• 고객의 비즈니스에 영향을 미치는 동향/혼란

제6장 면역 분석 시장, 제품별

• 서론
• 시약 및 키트
• 애널라이저

제7장 면역 분석 시장, 기술별

• 서론
• ELISA
• CLIA
• IFA
• 신속 테스트
• 웨스턴 블로팅
• ELISPOT
• 기타

제8장 면역 분석 시장, 검체별

• 서론
• 혈액
• 타액
• 소변
• 기타

제9장 면역 분석 시장, 용도별

• 서론
• 감염증
• 내분비학
• 심장병
• 자가면역질환
• 알레르기 진단
• 종양
• 뼈 및 미네랄 질병
• 약물 감시 및 검사
• 혈액 검사
• 신생아 스크리닝
• 기타

제10장 면역 분석 시장, 최종사용자별

• 서론
• 병원 및 진료소
• 임상 실험실
• 제약회사 및 바이오테크놀러지 기업, CRO
• 홈케어
• 혈액은행
• 학술 연구소

제11장 면역 분석 시장, 지역별

• 서론
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제12장 경쟁 구도

• 개요
• 주요 시장 진출기업의 전략/유력 기업
• 매출 분석
• 시장 점유율 분석
• 기업 평가 매트릭스
• 스타트업/중소기업 평가 매트릭스
• 경쟁 시나리오와 동향

제13장 기업 개요

• 주요 시장 진출기업
  • ABBOTT LABORATORIES
  • F. HOFFMANN-LA ROCHE LTD.
  • SIEMENS HEALTHINEERS AG
  • DANAHER CORPORATION
  • THERMO FISHER SCIENTIFIC INC.
  • REVVITY
  • BECTON, DICKINSON AND COMPANY
  • DIASORIN S.P.A.
  • BIO-RAD LABORATORIES, INC.
  • QUIDELORTHO CORPORATION
  • BIOMERIEUX
  • QIAGEN N.V.
  • SYSMEX CORPORATION
  • AGILENT TECHNOLOGIES, INC.
  • SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
• 기타 기업
  • MERCK KGAA
  • MERIDIAN BIOSCIENCE
  • BIO-TECHNE
  • CELLABS
  • ABNOVA CORPORATION
  • J. MITRA & CO. PVT. LTD.
  • TOSOH CORPORATION(TOSOH BIOSCIENCE)
  • CELL SCIENCES
  • ENZO BIOCHEM
  • CREATIVE DIAGNOSTICS
  • BOSTER BIOLOGICAL TECHNOLOGY
  • ELABSCIENCE
  • WAK-CHEMIE MEDICAL
  • SERACARE LIFESCIENCES INC.
  • EPITOPE DIAGNOSTICS
  • KAMIYA BIOMEDICAL COMPANY
  • GYROS PROTEIN TECHNOLOGIES
  • TRIVITRON HEALTHCARE
  • INBIOS INTERNATIONAL, INC.
  • MACCURA BIOTECHNOLOGY CO., LTD.

제14장 부록

영문목차

The global immunoassay market is valued at an estimated USD 35.0 billion in 2023 and is projected to reach USD 46.7 billion by 2028, at a CAGR of 5.9% during the forecast period. Market growth is driven by factors such as the rising prevalence of chronic and infectious diseases, innovations in the systems and technologies, supportive government policies and initiatives, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing.

"The reagents & kits to register the largest share of the immunoassay market, by product."

The global immunoassay market is segmented into reagents & kits and analyzers based on product. Market growth is largely driven by the repetitive use of reagents & kits for various diagnostic procedures coupled with the increase in the volume of immunoassay-based tests conducted worldwide. Moreover, the availability of better reagents & kits that offer efficient results and precision in diagnosis attributes to their growing requirement resulting in growth of the segment.

"Chemiluminescence Immunoassay segment to grow at a considerable rate among technology during the forecast period."

The immunoassay market is segmented into ELISA, Chemiluminescence Immunoassay (CLIA), Immunofluorescence assay (IFA), rapid tests, ELISpot, western blotting, and other technologies. CLIA tests help efficiently diagnose various chronic and infectious diseases compared to other techniques such as ELISA and radioimmunoassays, owing to benefits such as sensitivity, wide dynamic range, better speed, reduced interference, and high specificity.

"Infectious diseases segment accounted for the largest share in the immunoassay market, by application."

The global immunoassay market is segmented into infectious diseases, cardiology, endocrinology, oncology, bone & mineral disorders, autoimmune disorders, blood screening, allergy diagnostics, drug monitoring and testing, newborn screening, and other applications. The application segment of infectious diseases accounted for a considerable share in 2022, primarily due to the rapid diagnosis of infectious diseases coupled with the increasing incidence of diseases such as HIV/AIDS, malaria, hepatitis, and influenza, among others.

"Asia Pacific: The fastest-growing region in the immunoassay market."

The global immunoassay market is segmented into five regions - North America, Europe, the Asia Pacific, the Middle East & Africa, and Latin America. The Asia Pacific region is expected to grow at the highest rate during the forecast period in the immunoassay market. The high growth in the region is due to the presence of a large target population, and rising prevalence of chronic disorders in Asian countries.

The break-up of the profile of primary participants in the immunoassay market:

• By Company Type: Tier 1 - 28%, Tier 2 - 41%, and Tier 3 - 31%
• By Designation: C-level - 30%, D-level - 34%, and Others - 36%
• By Region: North America - 38%, Europe - 27%, Asia Pacific - 18%, Latin America - 6% and Middle East & Africa - 11%,

The key players in this market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), bioMerieux (France), QIAGEN N.V. (Germany), Sysmex Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., LTD. (China), Agilent Technologies (US), Merck KGaA (Germany), Meridian Bioscience (US), Bio-Techne (US), Cellabs (Australia), Abnova Corporation (Taiwan), J. Mitra & Co. Pvt. Ltd. (India), Tosoh Corporation (Japan), Cell Sciences (US), Enzo Biochem (US), Creative Diagnostics (US), Boster Biological Technology (US), Elabscience (US), WAK-Chemie Medical GmbH (Germany), Sera Care (US), Epitope Diagnostics Inc. (US), Kamiya Biomedical Company (US), Gyros Protein Technologies (Sweden), Trivitron Healthcare (India), InBios International Inc. (India), and Maccura Biotechnology Co., Ltd. (China).

Research Coverage:

This research report categorizes the immunoassay market by product (reagents & kits and analyzers), specimen type (blood, urine, saliva, and other specimens), technology (enzyme-linked immunosorbent assays, rapid tests, chemiluminescence immunoassay, immunofluorescence assay, enzyme-linked immunospot, western blotting, and other technologies), application (infectious diseases, blood screening, oncology, endocrinology, bone and mineral disorders, autoimmune disorders, cardiology, drug monitoring and testing, allergy diagnostics, newborn screening, and other applications), end user (clinical laboratories, hospitals and clinics, research & academic laboratories, blood banks, pharmaceutical and biotechnology companies & CROs, and home care settings), and region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the immunoassay market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the immunoassay market. This report covers the competitive analysis of upcoming startups in the immunoassay market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall immunoassay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (incidence of chronic and infectious diseases and growing awareness about early disease diagnosis, in systems and technologies, growth in biotechnology and biopharmaceutical industries, increasing adoption of immunoassay-based POC testing and rapid testing, supportive government policies, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing), restraints (requirements for approval of immunoassay instruments and consumables and technical hurdles of immunoassay kits), opportunities (opportunities in emerging economies, importance of companion diagnostics, development of condition-specific biomarkers and tests, integration of microfluidics in immunoassays, and improving immunoassay diagnostic technologies), and challenges (design challenges, complexities, and quality of antibodies, dearth of skilled professionals, unfavourable reimbursement scenario, and financial hurdles faced by physicians) influencing the growth of the immunoassay market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the immunoassay market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the immunoassay market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the immunoassay market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), and Thermo Fisher Scientific Inc. (US)among others in the immunoassay market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 INCLUSIONS & EXCLUSIONS
• 1.4 MARKET SCOPE
  • 1.4.1 MARKETS COVERED
  • FIGURE 1 IMMUNOASSAY MARKET SEGMENTATION
  • 1.4.2 REGIONS COVERED
  • 1.4.3 YEARS CONSIDERED
  • 1.4.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES
  • 1.6.1 IMPACT OF RECESSION: IMMUNOASSAY MARKET

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • FIGURE 2 RESEARCH DESIGN
  • 2.1.1 SECONDARY RESEARCH
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY RESEARCH
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• 2.2 MARKET SIZE ESTIMATION
  • FIGURE 5 REVENUE SHARE ANALYSIS
  • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 7 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • FIGURE 8 DATA TRIANGULATION METHODOLOGY
• 2.4 MARKET SHARE ANALYSIS
• 2.5 STUDY ASSUMPTIONS
  • 2.5.1 MARKET ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT
  • TABLE 1 RISK ASSESSMENT: IMMUNOASSAY MARKET
• 2.8 IMPACT OF RECESSION ON IMMUNOASSAY MARKET

3 EXECUTIVE SUMMARY

• FIGURE 9 IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
• FIGURE 10 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
• FIGURE 11 IMMUNOASSAY MARKET, BY SPECIMEN, 2023 VS. 2028 (USD BILLION)
• FIGURE 12 IMMUNOASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)
• FIGURE 13 IMMUNOASSAY MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
• FIGURE 14 GEOGRAPHICAL SNAPSHOT: IMMUNOASSAY MARKET

4 PREMIUM INSIGHTS

• 4.1 IMMUNOASSAY MARKET OVERVIEW
  • FIGURE 15 RISING INCIDENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
• 4.2 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT AND COUNTRY (2022)
  • FIGURE 16 REAGENTS & KITS AND US DOMINATED NORTH AMERICAN IMMUNOASSAY MARKET IN 2022
• 4.3 GEOGRAPHICAL SNAPSHOT: IMMUNOASSAY MARKET, 2023-2028
  • FIGURE 17 CHINA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD
• 4.4 REGIONAL MIX: IMMUNOASSAY MARKET, 2021-2028
  • FIGURE 18 ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING STUDY PERIOD
• 4.5 DEVELOPED VS. EMERGING ECONOMIES: IMMUNOASSAY MARKET, 2023-2028
  • FIGURE 19 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: IMMUNOASSAY MARKET
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing incidence of chronic and infectious diseases
  • FIGURE 21 INCREASING INCIDENCES OF DIABETES (IN MILLION)
    • 5.2.1.1.1 Growing use of immunoassays in oncology
  • TABLE 2 GLOBAL INCIDENCE OF MAJOR CANCERS IN MEN, 2020
  • TABLE 3 GLOBAL INCIDENCE OF MAJOR CANCERS IN WOMEN, 2020
    • 5.2.1.1.2 Increasing use of immunoassays in diagnostic applications
  • TABLE 4 TIME REQUIRED FOR DRUG DETECTION BY URINE TESTING
    • 5.2.1.1.3 Growing geriatric population
  • FIGURE 22 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (IN MILLION)
    • 5.2.1.2 Increasing need for blood donations
    • 5.2.1.3 Growth in biotechnology & biopharmaceutical industries
    • 5.2.1.4 Increasing adoption of immunoassay-based POC testing and rapid testing
    • 5.2.1.5 Supportive government regulatory policies and initiatives
    • 5.2.1.6 Increased drug abuse and use of cannabis
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Stringent approval criteria for immunoassay instruments and consumables
    • 5.2.2.2 Technical problems in immunoassay kits
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing growth opportunities in emerging economies
    • 5.2.3.2 Importance of companion diagnostics
  • TABLE 5 COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED, 2018-2022
    • 5.2.3.3 Development of condition-specific biomarkers and tests
  • TABLE 6 NEW TESTS LAUNCHED BY KEY PLAYERS, 2019-2023
    • 5.2.3.4 Integration of microfluidics in immunoassays
  • TABLE 7 LAB-ON-A-CHIP IMMUNOASSAY DEVICES/CHIPS/SYSTEMS OFFERED BY KEY PLAYERS
    • 5.2.3.5 Improved immunoassay diagnostic technologies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Design challenges, complexities, and low quality of antibodies
    • 5.2.4.2 Dearth of skilled professionals
    • 5.2.4.3 Unfavorable reimbursement scenario
• 5.3 REGULATORY ANALYSIS
  • 5.3.1 NORTH AMERICA
    • 5.3.1.1 US
  • TABLE 8 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
  • FIGURE 23 US: REGULATORY PROCESS FOR IVD DEVICES
    • 5.3.1.2 Canada
  • FIGURE 24 CANADA: REGULATORY PROCESS FOR IVD DEVICES
  • 5.3.2 EUROPE
  • TABLE 9 EUROPE: CLASSIFICATION OF IVD DEVICES
    • 5.3.2.1 Russia
  • TABLE 10 RUSSIA: CLASSIFICATION OF IVD DEVICES
  • 5.3.3 ASIA PACIFIC
    • 5.3.3.1 Japan
  • FIGURE 25 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
  • TABLE 11 JAPAN: CLASSIFICATION OF IVD REAGENTS
  • TABLE 12 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.3.3.2 China
  • TABLE 13 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.3.3.3 India
  • FIGURE 26 INDIA: REGULATORY PROCESS FOR IVD DEVICES
    • 5.3.3.4 Indonesia
  • TABLE 14 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
    • 5.3.3.5 South Korea
  • TABLE 15 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • 5.3.4 LATIN AMERICA
    • 5.3.4.1 Mexico
  • FIGURE 27 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
  • TABLE 16 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.3.4.2 Brazil
  • FIGURE 28 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
  • 5.3.5 MIDDLE EAST
    • 5.3.5.1 Saudi Arabia
  • TABLE 17 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • 5.3.6 AFRICA
• 5.4 TECHNOLOGY ANALYSIS
  • TABLE 18 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES
  • TABLE 19 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET
• 5.5 TRADE ANALYSIS
  • 5.5.1 TRADE ANALYSIS FOR IMMUNOASSAY PRODUCTS
  • TABLE 20 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 21 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018-2022 (USD MILLION)
• 5.6 PATENT ANALYSIS
• 5.7 VALUE CHAIN ANALYSIS
  • FIGURE 29 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
• 5.8 SUPPLY CHAIN ANALYSIS
  • FIGURE 30 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES
• 5.9 ECOSYSTEM/MARKET MAP
  • FIGURE 31 ECOSYSTEM/MARKET MAP: IMMUNOASSAY MARKET
  • 5.9.1 ROLE IN ECOSYSTEM
  • 5.9.2 KEY PLAYERS IN IMMUNOASSAY MARKET
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 22 PORTER'S FIVE FORCES
  • 5.10.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10.2 BARGAINING POWER OF SUPPLIERS
  • 5.10.3 BARGAINING POWER OF BUYERS
  • 5.10.4 THREAT OF SUBSTITUTES
  • 5.10.5 THREAT FROM NEW ENTRANTS
• 5.11 KEY CONFERENCES & EVENTS IN 2023-2024
  • TABLE 23 KEY CONFERENCES & EVENTS IN 2023-2024
• 5.12 PRICING ANALYSIS
  • TABLE 24 PRICE RANGE FOR IMMUNOASSAY PRODUCTS
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • TABLE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • 5.13.2 BUYING CRITERIA
  • FIGURE 33 KEY BUYING CRITERIA FOR TOP END USERS
  • TABLE 26 KEY BUYING CRITERIA, BY TOP END USER
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

6 IMMUNOASSAY MARKET, BY PRODUCT

• 6.1 INTRODUCTION
  • TABLE 27 IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
• 6.2 REAGENTS & KITS
  • TABLE 28 KEY REAGENTS & KITS AVAILABLE
  • TABLE 29 IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 30 IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • 6.2.1 ELISA REAGENTS & KITS
    • 6.2.1.1 Increased use of high-throughput screening in drug discovery programs to drive segment
  • TABLE 31 ELISA REAGENTS & KITS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.2.2 RAPID TEST REAGENTS & KITS
    • 6.2.2.1 High demand for rapid test reagents & kits in remote areas for preliminary screening tests to drive segment
  • TABLE 32 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.2.3 ELISPOT REAGENTS & KITS
    • 6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to drive segment
  • TABLE 33 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.2.4 CLIA REAGENTS & KITS
    • 6.2.4.1 Better diagnosis and higher specificity to drive segment
  • TABLE 34 CLIA REAGENTS & KITS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.2.5 IFA REAGENTS & KITS
    • 6.2.5.1 Better adaptability in clinical diagnostics and medicine to drive segment
  • TABLE 35 IFA REAGENTS & KITS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.2.6 WESTERN BLOT REAGENTS & KITS
    • 6.2.6.1 Western blotting reagents & kits to be considered gold standard for COVID-19 test result validation
  • TABLE 36 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.2.7 OTHER REAGENTS & KITS
  • TABLE 37 OTHER REAGENTS & KITS MARKET, BY REGION, 2021-2028 (USD MILLION)
• 6.3 ANALYZERS
  • TABLE 38 KEY ANALYZERS AVAILABLE
  • TABLE 39 IMMUNOASSAY MARKET FOR ANALYZERS, BY REGION, 2021-2028 (USD MILLION)
  • 6.3.1 IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE
  • TABLE 40 IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
    • 6.3.1.1 Open-ended systems
      • 6.3.1.1.1 Better flexibility and wider availability to drive segment
  • TABLE 41 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.1.2 Closed-ended systems
      • 6.3.1.2.1 Higher precision and better automation to drive segment
  • TABLE 42 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.3.2 IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE
  • TABLE 43 IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
    • 6.3.2.1 Rental purchase
      • 6.3.2.1.1 Increased convenience and lack of liability to drive segment
  • TABLE 44 RENTAL PURCHASE MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 6.3.2.2 Outright purchase
      • 6.3.2.2.1 Inflated cost of immunoassay testing technologies to limit market
  • TABLE 45 OUTRIGHT PURCHASE MARKET, BY REGION, 2021-2028 (USD MILLION)

7 IMMUNOASSAY MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
  • TABLE 46 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
• 7.2 ELISA
  • 7.2.1 BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET
  • TABLE 47 KEY ELISA TECHNOLOGIES AVAILABLE
  • TABLE 48 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2021-2028 (USD MILLION)
• 7.3 CLIA
  • 7.3.1 GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO DRIVE MARKET
  • TABLE 49 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2021-2028 (USD MILLION)
• 7.4 IFA
  • 7.4.1 IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND NON-BIOLOGICAL MOLECULES
  • TABLE 50 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2021-2028 (USD MILLION)
• 7.5 RAPID TESTS
  • 7.5.1 FASTER RESULTS AND EASE OF USE TO DRIVE MARKET
  • TABLE 51 KEY RAPID TESTS AVAILABLE
  • TABLE 52 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2021-2028 (USD MILLION)
• 7.6 WESTERN BLOTTING
  • 7.6.1 ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES TO DRIVE MARKET
  • TABLE 53 WESTERN BLOTTING SYSTEMS AVAILABLE
  • TABLE 54 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2021-2028 (USD MILLION)
• 7.7 ELISPOT
  • 7.7.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY TO DRIVE MARKET
  • TABLE 55 IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2021-2028 (USD MILLION)
• 7.8 OTHER TECHNOLOGIES
  • TABLE 56 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)

8 IMMUNOASSAY MARKET, BY SPECIMEN

• 8.1 INTRODUCTION
  • TABLE 57 IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
• 8.2 BLOOD
  • 8.2.1 HIGH RELIABILITY AND ADVANCEMENTS IN HEALTHCARE SYSTEM TO DRIVE MARKET
  • TABLE 58 IMMUNOASSAY MARKET FOR BLOOD, BY REGION, 2021-2028 (USD MILLION)
• 8.3 SALIVA
  • 8.3.1 DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET
  • TABLE 59 IMMUNOASSAY MARKET FOR SALIVA, BY REGION, 2021-2028 (USD MILLION)
• 8.4 URINE
  • 8.4.1 INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO DRIVE MARKET
  • TABLE 60 IMMUNOASSAY MARKET FOR URINE, BY REGION, 2021-2028 (USD MILLION)
• 8.5 OTHER SPECIMENS
  • TABLE 61 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2021-2028 (USD MILLION)

9 IMMUNOASSAY MARKET, BY APPLICATION

• 9.1 INTRODUCTION
  • TABLE 62 IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• 9.2 INFECTIOUS DISEASES
  • 9.2.1 RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET
  • TABLE 63 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
• 9.3 ENDOCRINOLOGY
  • 9.3.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET
  • TABLE 64 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION, 2021-2028 (USD MILLION)
• 9.4 CARDIOLOGY
  • 9.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
  • TABLE 65 KEY PRODUCTS FOR CARDIOLOGY APPLICATIONS
  • TABLE 66 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION, 2021-2028 (USD MILLION)
• 9.5 AUTOIMMUNE DISORDERS
  • 9.5.1 HIGH INCIDENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
  • TABLE 67 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021-2028 (USD MILLION)
• 9.6 ALLERGY DIAGNOSTICS
  • 9.6.1 GROWING PREVALENCE OF ALLERGIES TO DRIVE MARKET
  • TABLE 68 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
• 9.7 ONCOLOGY
  • 9.7.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY DETECTION TO DRIVE MARKET
  • TABLE 69 INCREASING INCIDENCE OF CANCER, BY REGION, 2021 VS. 2030 VS. 2040 (MILLION)
  • TABLE 70 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)
• 9.8 BONE & MINERAL DISORDERS
  • 9.8.1 INCREASING PREVALENCE OF BONE DISEASES TO DRIVE MARKET
  • TABLE 71 KEY PRODUCTS FOR BONE & MINERAL DISORDERS
  • TABLE 72 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
• 9.9 DRUG MONITORING AND TESTING
  • 9.9.1 RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO DRIVE MARKET
  • TABLE 73 KEY PRODUCTS FOR DRUG MONITORING
  • TABLE 74 KEY IMMUNOASSAY PRODUCTS FOR DRUG TESTING
  • TABLE 75 IMMUNOASSAY MARKET FOR DRUG MONITORING AND TESTING, BY REGION, 2021-2028 (USD MILLION)
• 9.10 BLOOD SCREENING
  • 9.10.1 RISING NUMBER OF BLOOD DONATIONS TO DRIVE MARKET
  • TABLE 76 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION, 2021-2028 (USD MILLION)
• 9.11 NEWBORN SCREENING
  • 9.11.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET
  • TABLE 77 KEY PRODUCTS FOR NEWBORN SCREENING
  • TABLE 78 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION, 2021-2028 (USD MILLION)
• 9.12 OTHER APPLICATIONS
  • TABLE 79 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)

10 IMMUNOASSAY MARKET, BY END USER

• 10.1 INTRODUCTION
  • TABLE 80 IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
• 10.2 HOSPITALS & CLINICS
  • 10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUME TO DRIVE MARKET
  • TABLE 81 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021-2028 (USD MILLION)
• 10.3 CLINICAL LABORATORIES
  • 10.3.1 INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET
  • TABLE 82 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
• 10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS
  • 10.4.1 GROWING DRUG DISCOVERY AND INCREASING R&D INVESTMENTS TO DRIVE MARKET
  • TABLE 83 IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION)
• 10.5 HOME CARE SETTINGS
  • 10.5.1 RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO DRIVE MARKET
  • TABLE 84 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2021-2028 (USD MILLION)
• 10.6 BLOOD BANKS
  • 10.6.1 RISING DEMAND FOR BLOOD AND INCREASING NUMBER OF ACCIDENTS TO DRIVE MARKET
  • TABLE 85 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2021-2028 (USD MILLION)
• 10.7 RESEARCH & ACADEMIC LABORATORIES
  • 10.7.1 RISING NUMBER OF MEDICAL COLLEGES AND UNIVERSITIES TO DRIVE MARKET
  • TABLE 86 IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION)

11 IMMUNOASSAY MARKET, BY REGION

• 11.1 INTRODUCTION
  • TABLE 87 IMMUNOASSAY MARKET, BY REGION, 2021-2028 (USD MILLION)
• 11.2 NORTH AMERICA
  • FIGURE 34 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT
  • TABLE 88 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 89 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 90 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 91 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 92 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 93 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 94 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 95 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 96 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.2.1 NORTH AMERICA: RECESSION IMPACT
  • 11.2.2 US
    • 11.2.2.1 High healthcare expenditure and growth in geriatric population to drive market
  • TABLE 97 US: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 98 US: IMMUNOASSAY ASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 99 US: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 100 US: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 101 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 102 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 103 US: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 104 US: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing government support and rising incidence of chronic diseases to drive market
  • TABLE 105 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 106 CANADA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 107 CANADA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 108 CANADA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 109 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 110 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 111 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 112 CANADA: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
• 11.3 EUROPE
  • TABLE 113 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 114 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 115 EUROPE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 116 EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 117 EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 118 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 119 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 120 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 121 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.1 EUROPE: RECESSION IMPACT
  • 11.3.2 GERMANY
    • 11.3.2.1 Germany to dominate European immunoassay market during forecast period
  • TABLE 122 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 123 GERMANY: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 124 GERMANY: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 125 GERMANY: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 126 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 127 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 128 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 129 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.3 ITALY
    • 11.3.3.1 Growing geriatric population and increasing support for research to drive market
  • TABLE 130 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 131 ITALY: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 132 ITALY: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 133 ITALY: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 134 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 135 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 136 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 137 ITALY: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.4 FRANCE
    • 11.3.4.1 Rising use of POC testing and favorable reimbursement policies to drive market
  • TABLE 138 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 139 FRANCE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 140 FRANCE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 141 FRANCE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 142 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 143 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 144 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 145 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.5 SPAIN
    • 11.3.5.1 Increasing adoption of technologically advanced immunoassay systems to drive market
  • TABLE 146 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 147 SPAIN: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 148 SPAIN: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 149 SPAIN: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 150 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 151 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 152 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 153 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.6 UK
    • 11.3.6.1 Government support for disease diagnostics and favorable investment scenario to drive market
  • TABLE 154 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 155 UK: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 156 UK: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 157 UK: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 158 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 159 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 160 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 161 UK: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.7 RUSSIA
    • 11.3.7.1 Lack of reimbursement and delays in approval to limit market
  • TABLE 162 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 163 RUSSIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 164 RUSSIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 165 RUSSIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 166 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 167 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 168 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 169 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.8 REST OF EUROPE
  • TABLE 170 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 171 REST OF EUROPE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 172 REST OF EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 173 REST OF EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 174 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 175 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 176 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 177 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
• 11.4 ASIA PACIFIC
  • FIGURE 35 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT
  • TABLE 178 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 180 ASIA PACIFIC: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 181 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 183 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 184 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 185 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 186 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
  • 11.4.2 JAPAN
    • 11.4.2.1 Increasing investments in healthcare technologies and research activities to drive market
  • TABLE 187 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 188 JAPAN: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 189 JAPAN: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 190 JAPAN: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 191 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 192 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 193 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 194 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.3 CHINA
    • 11.4.3.1 Increasing government investment and rising geriatric population to drive market
  • TABLE 195 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 196 CHINA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 197 CHINA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 198 CHINA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 199 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 200 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 201 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 202 CHINA: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.4 INDIA
    • 11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market
  • TABLE 203 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 204 INDIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 205 INDIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 206 INDIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 207 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 208 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 209 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 210 INDIA: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Increasing incidence of cancer and rising blood donations to drive market
  • TABLE 211 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 212 AUSTRALIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 213 AUSTRALIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 214 AUSTRALIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 215 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 216 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 217 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 218 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Rising healthcare spending and investments in research to drive market
  • TABLE 219 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 220 SOUTH KOREA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 221 SOUTH KOREA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 222 SOUTH KOREA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 223 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 224 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 225 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 226 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.7 INDONESIA
    • 11.4.7.1 Increasing geriatric population and favorable government healthcare policies to drive market
  • TABLE 227 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 228 INDONESIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 229 INDONESIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 230 INDONESIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 231 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 232 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 233 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 234 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.8 REST OF ASIA PACIFIC
  • TABLE 235 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 236 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 237 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 238 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 239 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 240 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 241 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 242 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)

• 11.5 LATIN AMERICA
  • TABLE 243 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 244 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 246 LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 247 LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 248 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 249 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 250 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 251 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.5.1 LATIN AMERICA: RECESSION IMPACT
  • 11.5.2 BRAZIL
    • 11.5.2.1 Brazil commanded largest share in Latin American immunoassay market in 2022
  • TABLE 252 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 253 BRAZIL: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 254 BRAZIL: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 255 BRAZIL: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 256 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 257 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 258 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 259 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.5.3 MEXICO
    • 11.5.3.1 Increasing geriatric population and rising medical tourism to drive market
  • TABLE 260 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 261 MEXICO: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 262 MEXICO: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 263 MEXICO: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 264 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 265 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 266 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 267 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.5.4 REST OF LATIN AMERICA
  • TABLE 268 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 269 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 270 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 271 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 272 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 273 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 274 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 275 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 LACK OF SKILLED LAB PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT GROWTH
  • 11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
  • TABLE 276 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 277 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 278 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 279 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021-2028 (USD MILLION)
  • TABLE 280 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 281 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021-2028 (USD MILLION)
  • TABLE 282 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 283 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2021-2028 (USD MILLION)

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF KEY STRATEGIES ADOPTED BY MAJOR PLAYERS
  • TABLE 284 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOASSAY MARKET
• 12.3 REVENUE ANALYSIS
  • FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS
• 12.4 MARKET SHARE ANALYSIS
  • TABLE 285 DEGREE OF COMPETITION IN IMMUNOASSAY MARKET
  • FIGURE 37 IMMUNOASSAY MARKET SHARE, BY KEY PLAYER (2022)
• 12.5 COMPANY EVALUATION MATRIX
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • FIGURE 38 COMPANY EVALUATION MATRIX, 2022
  • 12.5.5 COMPANY FOOTPRINT
  • TABLE 286 OVERALL FOOTPRINT
  • TABLE 287 PRODUCT FOOTPRINT
  • TABLE 288 REGIONAL FOOTPRINT
• 12.6 START-UP/SME EVALUATION MATRIX
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • FIGURE 39 START-UP/SME EVALUATION MATRIX, 2022
  • 12.6.5 COMPETITIVE BENCHMARKING
  • TABLE 289 KEY START-UPS/SMES IN IMMUNOASSAY MARKET
• 12.7 COMPETITIVE SCENARIOS AND TRENDS
  • 12.7.1 KEY PRODUCT LAUNCHES AND APPROVALS
  • TABLE 290 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020-SEPTEMBER 2023
  • 12.7.2 KEY DEALS
  • TABLE 291 KEY DEALS, JANUARY 2020-SEPTEMBER 2023
  • 12.7.3 OTHER KEY DEVELOPMENTS
  • TABLE 292 OTHER KEY DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2023

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
• (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
• 13.1.1 ABBOTT LABORATORIES
• TABLE 293 ABBOTT LABORATORIES: COMPANY OVERVIEW
• FIGURE 40 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
• 13.1.2 F. HOFFMANN-LA ROCHE LTD.
• TABLE 294 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
• FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
• 13.1.3 SIEMENS HEALTHINEERS AG
• TABLE 295 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
• FIGURE 42 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
• 13.1.4 DANAHER CORPORATION
• TABLE 296 DANAHER CORPORATION: COMPANY OVERVIEW
• FIGURE 43 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
• 13.1.5 THERMO FISHER SCIENTIFIC INC.
• TABLE 297 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
• 13.1.6 REVVITY
• TABLE 298 REVVITY: COMPANY OVERVIEW
• FIGURE 45 REVVITY: COMPANY SNAPSHOT (2022)
• 13.1.7 BECTON, DICKINSON AND COMPANY
• TABLE 299 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
• FIGURE 46 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
• 13.1.8 DIASORIN S.P.A.
• TABLE 300 DIASORIN S.P.A.: COMPANY OVERVIEW
• FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
• 13.1.9 BIO-RAD LABORATORIES, INC.
• TABLE 301 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
• FIGURE 48 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
• 13.1.10 QUIDELORTHO CORPORATION
• TABLE 302 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
• FIGURE 49 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
• 13.1.11 BIOMERIEUX
• TABLE 303 BIOMERIEUX: COMPANY OVERVIEW
• FIGURE 50 BIOMERIEUX: COMPANY SNAPSHOT (2022)
• 13.1.12 QIAGEN N.V.
• TABLE 304 QIAGEN N.V.: COMPANY OVERVIEW
• FIGURE 51 QIAGEN N.V.: COMPANY SNAPSHOT (2022)
• 13.1.13 SYSMEX CORPORATION
• TABLE 305 SYSMEX CORPORATION: COMPANY OVERVIEW
• FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
• 13.1.14 AGILENT TECHNOLOGIES, INC.
• TABLE 306 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
• FIGURE 53 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
• 13.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
• TABLE 307 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
• FIGURE 54 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022)
• 13.2 OTHER PLAYERS
  • 13.2.1 MERCK KGAA
  • 13.2.2 MERIDIAN BIOSCIENCE
  • 13.2.3 BIO-TECHNE
  • 13.2.4 CELLABS
  • 13.2.5 ABNOVA CORPORATION
  • 13.2.6 J. MITRA & CO. PVT. LTD.
  • 13.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCE)
  • 13.2.8 CELL SCIENCES
  • 13.2.9 ENZO BIOCHEM
  • 13.2.10 CREATIVE DIAGNOSTICS
  • 13.2.11 BOSTER BIOLOGICAL TECHNOLOGY
  • 13.2.12 ELABSCIENCE
  • 13.2.13 WAK-CHEMIE MEDICAL
  • 13.2.14 SERACARE LIFESCIENCES INC.
  • 13.2.15 EPITOPE DIAGNOSTICS
  • 13.2.16 KAMIYA BIOMEDICAL COMPANY
  • 13.2.17 GYROS PROTEIN TECHNOLOGIES
  • 13.2.18 TRIVITRON HEALTHCARE
  • 13.2.19 INBIOS INTERNATIONAL, INC.
  • 13.2.20 MACCURA BIOTECHNOLOGY CO., LTD.
• *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS